GYRE
Gyre Therapeutics Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$685.89M
P/E Ratio
356.00
EPS
$0.02
Beta
6.40
52W High
$11.78
52W Low
$6.57
50-Day MA
$7.77
200-Day MA
$7.68
Dividend Yield
—
Profit Margin
4.31%
Forward P/E
78.12
PEG Ratio
—
About Gyre Therapeutics Inc.
Gyre Therapeutics Inc. is a biopharmaceutical innovator focused on developing groundbreaking therapies for rare and complex diseases. Leveraging a proprietary platform, the company accelerates the discovery and commercialization of precision treatments tailored to address significant unmet medical needs. With a strong commitment to scientific rigor and patient-centered outcomes, Gyre is strategically positioned to advance its pipeline in gene therapy and precision medicine. Their dedication to research excellence and strategic partnerships highlights their potential for substantial growth in an increasingly competitive biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | $116.59M |
| Gross Profit (TTM) | $111.17M |
| EBITDA | $14.01M |
| Operating Margin | 0.32% |
| Return on Equity | 8.21% |
| Return on Assets | 4.93% |
| Revenue/Share (TTM) | $1.30 |
| Book Value | $1.16 |
| Price-to-Book | 6.12 |
| Price-to-Sales (TTM) | 5.88 |
| EV/Revenue | 5.13 |
| EV/EBITDA | 42.66 |
| Quarterly Earnings Growth (YoY) | 166.20% |
| Quarterly Revenue Growth (YoY) | 33.40% |
| Shares Outstanding | $91.31M |
| Float | $20.95M |
| % Insiders | 86.69% |
| % Institutions | 3.69% |
Analyst Ratings
Consensus ($18.67 target)
3
BuyData last updated: 4/8/2026